Organon & Co., founded in 2021 and based in Jersey City, New Jersey, is a global healthcare company dedicated to women's health. The company focuses on delivering innovative solutions through a robust portfolio that includes contraceptives, fertility treatments, and therapeutics for women’s health conditions.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| ORGNON 2.88% 2028-04-30 EUROrganon & Co. | United States | 2028-04-30 | 2.875 | 3.99 |
| ORGNON 6.75% 2034-05-15 USDOrganon & Co. | United States | 2034-05-15 | 6.750 | 7.59 |
| ORGNON 6.75% 2034-05-15 USDOrganon & Co. | United States | 2034-05-15 | 6.750 | 7.58 |
| ORGNON 7.88% 2034-05-15 USDOrganon & Co. | United States | 2034-05-15 | 7.875 | 9.44 |
| ORGNON 7.88% 2034-05-15 USDOrganon & Co. | United States | 2034-05-15 | 7.875 | 9.29 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Since its inception, Organon has actively engaged in the bond market, first issuing bonds shortly after its spin-off from Merck & Co. in 2021. Notably, their inaugural issuance totaled $3.75 billion, which was utilized for general corporate purposes and debt refinancing. As of October 2023, Organon's bonds have demonstrated competitive yields within the industry, driven by their strategic focus on women's health, and featured a mix of fixed-rate and convertible bonds designed to appeal to a diverse range of investors.